LUNGNMSHealthcare·Medical Devices#97 in industry

Pulmonx Corporation

Reports in 2d· 2026-04-29

-26.9% · 90d

$1.28

+0.01 (+0.79%)

After-Hours $1.28(+0.00)

News

(2)

April 2026

Apr 22, 20265 days agoARSHealthcare

Pulmonx Corp (LUNG) files annual report detailing full year financials and strategy

LUNGPulmonx Corp

As an expert financial analyst and educator, I am ready to break down this filing for you! However, it appears the actual content of the Annual Report (ARS) document was not included in the submission. 📄 To give you the comprehensive, beginner-friendly breakdown you requested, I need the text or t

Read summaryView on SEC EDGAR

Apr 22, 20265 days agoDEF 14AHealthcare

Pulmonx Proxy Statement outlines votes on directors, auditors, and executive pay

LUNGPulmonx Corp

# 🧾 What This Document Is 📜 This document is a **Proxy Statement (DEF 14A)**, which is essentially an official information packet sent to shareholders before a big vote. Think of it as the rulebook and instruction manual for the company’s annual meeting. It doesn't contain financial results for t

Read summaryView on SEC EDGAR

Key Data

Market Cap$54.1M

Open$1.27

Prev Close$1.27

Day Range$1.26 – $1.29

52W Range$1.13 – $5.46

Volume325,030

P/E (TTM)—

EPS$-1.33

Dividend Yield—

Beta0.19

Profit Margin-59.67%

Revenue Growth-4.90%

Price Target$5.17(+303.6%)

Next Earnings2026-04-29(2d)

Analyst Ratings

Buy5 analysts

Buy 3Hold 2Sell 0

About

Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Healthcare · Medical Devices

296 employees

pulmonx.com